Ashleigh Palmer - Jan 18, 2023 Form 4 Insider Report for Provention Bio, Inc. (PRVB)

Role
Director and CEO, Director
Signature
/s/ Thierry Chauche, as attorney-in-fact
Stock symbol
PRVB
Transactions as of
Jan 18, 2023
Transactions value $
-$187,651
Form type
4
Date filed
1/20/2023, 07:00 PM
Previous filing
Jan 18, 2023
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRVB Common Stock Options Exercise $60.4K +24.2K +0.94% $2.50* 2.59M Jan 18, 2023 Direct
transaction PRVB Common Stock Sale -$248K -24.2K -0.93% $10.27 2.57M Jan 18, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRVB Stock Option (right to buy) Options Exercise $0 -24.2K -4.46% $0.00 518K Jan 18, 2023 Common Stock 24.2K $2.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.12 to $10.42 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The option is fully vested.